John L. Joyal
Nessuna posizione attualmente
Profilo
John L.
Joyal has been Vice President of Discovery Research of Molecular Insight Pharmaceuticals, Inc. since January 2008.
He joined Molecular Insight as Director of Biology in 2005.
He has over 20 years of basic research and drug discovery experience with expertise in cell and molecular biology in the areas of receptor biology, signal transduction pathways, and in vitro assay development.
Prior to joining Phylogix in 2004, Dr. Joyal held various positions at Praecis Pharmaceuticals including Director of Cell Biology, where he initiated or participated in the establishment of numerous research projects focusing on the development of novel therapeutics for the treatment of oncology, inflammation, infectious disease, and neurological disorders.
He did his post-doctoral training at Harvard Medical School/Brigham and Women's Hospital examining novel interactions between calmodulin and proteins involved in breast carcinogenesis and growth factor signaling.
Dr. Joyal received a PhD in biology from Tufts University.
Precedenti posizioni note di John L. Joyal
| Società | Posizione | Fine |
|---|---|---|
Praecis Pharmaceuticals, Inc.
 Praecis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Praecis Pharmaceuticals, Inc. develops drugs and therapies for the treatment of cancer. The firm also develops peptide-based drugs. The company was founded 1993 and is headquartered in Waltham, MA. | Corporate Officer/Principal | 01/01/2004 |
Phylogix, Inc.
 Phylogix, Inc. Pharmaceuticals: MajorHealth Technology Phylogix, Inc. develops therapeutic drugs. It conducts research on tissue protection and oncology. The firm develops drug candidates in preclinical development, called FRIL to protect cancer patients from the toxic side-effects of chemotherapy. The company was founded in 1998 and is headquartered in Waltham, MA | Direttore Tecnico/Scientifico/R&S | - |
Molecular Insight Pharmaceuticals, Inc.
 Molecular Insight Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Molecular Insight Pharmaceuticals, Inc. engages in developing and commercializing innovative molecular imaging pharmaceuticals and targeted radiotherapeutics to diagnose and treat disease. The company was founded in 1997 and the company is headquartered in Cambridge, MA. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di John L. Joyal
| Tufts University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Molecular Insight Pharmaceuticals, Inc.
Molecular Insight Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Molecular Insight Pharmaceuticals, Inc. engages in developing and commercializing innovative molecular imaging pharmaceuticals and targeted radiotherapeutics to diagnose and treat disease. The company was founded in 1997 and the company is headquartered in Cambridge, MA. | Health Services |
Phylogix, Inc.
Phylogix, Inc. Pharmaceuticals: MajorHealth Technology Phylogix, Inc. develops therapeutic drugs. It conducts research on tissue protection and oncology. The firm develops drug candidates in preclinical development, called FRIL to protect cancer patients from the toxic side-effects of chemotherapy. The company was founded in 1998 and is headquartered in Waltham, MA | Health Technology |
Praecis Pharmaceuticals, Inc.
Praecis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Praecis Pharmaceuticals, Inc. develops drugs and therapies for the treatment of cancer. The firm also develops peptide-based drugs. The company was founded 1993 and is headquartered in Waltham, MA. | Health Technology |
- Borsa valori
- Insiders
- John L. Joyal
